Rivaroxaban treatment (15 mg/kg/d) can significantly reduce the maximal aortic diameter and suppress experimental abdominal aortic aneurysm progression in ApoE-deficient (ApoE-/-) mice (Ding et al., 2021). Here, APOE is linked to abdominal aortic aneurysm.